RxDoctor Payments Data

Justin Reimink

Medical · Grand Rapids, MINPI 1417266404

Payments from drug & device makers

$1,076in general payments, 2019–2025

Across 28 payments — averaging $38.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$245
  • Medtronic$166
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$154
  • Novartis$132
  • Boehringer Ingelheim$125
  • Boston Scientific$82
  • plus $172 from 7 others

What the payments were for

  • Food & beverage$1,06399%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,076 in reported general payments places this provider in the 65th percentile of 755 medical providers in Michigan.

See all medical providers in Michigan

Medicare billing

Part B allowed, 2024
$17,135
Medicare patients
158
Services billed
296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban344$401,414
FarxigaDapagliflozin Propanediol123$130,604
EntrestoSacubitril/Valsartan87$111,741
JardianceEmpagliflozin88$101,492
XareltoRivaroxaban60$80,742
Repatha SureclickEvolocumab36$29,146
Metoprolol Succinate542$12,090
BrilintaTicagrelor11$8,391
Atorvastatin Calcium271$4,882
Ranolazine ErRanolazine41$4,273
Dofetilide20$3,635
Rosuvastatin Calcium168$3,479
Torsemide195$3,125
Carvedilol166$2,762
Diltiazem 24hr Er (Cd)Diltiazem Hcl80$2,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$401,414344 claims
AstraZenecaFarxiga, Brilinta$41$138,995134 claims
NovartisEntresto$132$111,74187 claims
Boehringer IngelheimJardiance$125$101,49288 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 755 medical providers in Michigan.

Other medical in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →